- Home
- RMAX vs NYXH Comparison
RMAX vs NYXH Comparison
Compare RMAX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- NYXH
- Stock Information
- Founded
- RMAX 1973
- NYXH 2009
- Country
- RMAX United States
- NYXH Belgium
- Employees
- RMAX N/A
- NYXH N/A
- Industry
- RMAX Real Estate
- NYXH Medical/Dental Instruments
- Sector
- RMAX Finance
- NYXH Health Care
- Exchange
- RMAX Nasdaq
- NYXH Nasdaq
- Market Cap
- RMAX 187.5M
- NYXH 185.5M
- IPO Year
- RMAX 2013
- NYXH 2021
- Fundamental
- Price
- RMAX $8.42
- NYXH $6.46
- Analyst Decision
- RMAX Hold
- NYXH Strong Buy
- Analyst Count
- RMAX 1
- NYXH 3
- Target Price
- RMAX $9.00
- NYXH $15.00
- AVG Volume (30 Days)
- RMAX 200.3K
- NYXH 79.3K
- Earning Date
- RMAX 10-30-2025
- NYXH 11-05-2025
- Dividend Yield
- RMAX N/A
- NYXH N/A
- EPS Growth
- RMAX N/A
- NYXH N/A
- EPS
- RMAX 0.48
- NYXH N/A
- Revenue
- RMAX $298,162,000.00
- NYXH $5,793,306.00
- Revenue This Year
- RMAX N/A
- NYXH $85.62
- Revenue Next Year
- RMAX N/A
- NYXH $320.09
- P/E Ratio
- RMAX $17.53
- NYXH N/A
- Revenue Growth
- RMAX N/A
- NYXH 2.94
- 52 Week Low
- RMAX $6.90
- NYXH $4.35
- 52 Week High
- RMAX $14.31
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- RMAX 33.96
- NYXH 68.53
- Support Level
- RMAX $9.10
- NYXH $4.36
- Resistance Level
- RMAX $9.44
- NYXH $5.13
- Average True Range (ATR)
- RMAX 0.31
- NYXH 0.30
- MACD
- RMAX -0.18
- NYXH 0.23
- Stochastic Oscillator
- RMAX 1.57
- NYXH 89.90
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.